ArticleTargeted oncology2026

First-Line Therapy for Advanced Renal Cell Carcinoma: Score-Matched Analysis of Dual Combination Immunotherapy versus Combination of Tyrosine Kinase Inhibitors and Immunotherapy in the TOURS Multicenter Study.

Hiromitsu Watanabe et al.PubMed ↗Publisher ↗

No numbers read from the abstract.